Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis.

Kennedy, N. A.; Warner, B; Johnston, E L; Flanders, L; Hendy, P; Ding, N S; Harris, R; Fadra, A S; Basquill, C; Lamb, C A; Cameron, F L; Murray, C D; Parkes, M; Gooding, I; Ahmad, Tariq; Gaya, D R; Mann, S; Lindsay, J O; Gordon, J; Satsangi, J; Hart, A; McCartney, S; Irving, P; Lees, C W

View/Open

Open Access article (447.4Kb)

URI

http://hdl.handle.net/11287/600306

Author

Kennedy, N. A.

Warner, B

Johnston, E L

Flanders, L

Hendy, P

Ding, N S

Harris, R

Fadra, A S

Basquill, C

Lamb, C A

Cameron, F L

Murray, C D

Parkes, M

Gooding, I

Ahmad, Tariq

Gaya, D R

Mann, S

Lindsay, J O

Gordon, J

Satsangi, J

Hart, A

McCartney, S

Irving, P

Lees, C W

Date

2016-02-19

Journal

Alimentary pharmacology & therapeutics

Type

Journal Article
Meta-Analysis
Systematic review

Publisher

Wiley

DOI

10.1111/apt.13547

Rights

Archived with thanks to Alimentary Pharmacology & Therapeutics. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Metadata

Show full item record

Abstract

Infliximab and adalimumab have established roles in inflammatory bowel disease (IBD) therapy. UK regulators mandate reassessment after 12 months' anti-TNF therapy for IBD, with consideration of treatment withdrawal. There is a need for more data to establish the relapse rates following treatment cessation.

Citation

Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis. 2016 Apr;43(8):910-923 Aliment. Pharmacol. Ther.

Publisher URL

http://dx.doi.org/10.1111/apt.13547

Note

This article is freely available via Open Access. Click on the 'Additional Link' above to access the full-text from the publisher's site.